Quantcast

Industry news that matters to you.  Learn more

IBM and Cleveland Clinic Use Watson to Advance Genomic Research for Cancer Care Pilot

IBM (NYSE: IBM) recently announced a new initiative to accelerate the adoption of genomic based medicine at Cleveland Clinic. Researchers at Cleveland Clinic will use IBM Watson technology in the area of genomic research to help oncologists deliver personalized medicine by uncovering new cancer treatment options for patients.

IBM, Coriell Life Sciences and CareKinesis Deliver Personalized Medicine to the Elderly Via the Cloud

IBM (NYSE: IBM) recently announced a collaboration with Coriell Life Sciences, a provider of genetic analysis at point of care, and CareKinesis, Inc., a Medication Risk Mitigation® pharmacy services firm, to bring personalized medicine to the elderly based on analyzing and storing genetic data in a secure cloud environment.

The New York Genome Center And IBM Watson Group Announce Collaboration To Advance Genomic Medicine

The New York Genome Center (NYGC) and IBM (NYSE: IBM) recently announced an initiative to accelerate a new era of genomic medicine with the use of IBM’s Watson cognitive system. IBM and NYGC will test a unique Watson prototype designed specifically for genomic research as a tool to help oncologists deliver more personalized care to cancer patients.

IBM and Swiss Hospital Test New Tool for Diagnosing Cancer

IBM (NYSE: IBM) scientists are collabo-rating with pathologists at the University Hospital Zürich to test a new proto-type tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

Biomarker Briefs: July 25, 2011

Biomarker Briefs is an occasionally recurring series highlighting particularly interesting articles on biomarkers and/or personalized medicine.